← Leaderboards
Garry John Southan
Inotek Pharmaceuticals Corporation
$13,828,224
Attributed
$13,828,224
Total exposure
21
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2011–18$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$13,828,224 · 21
By mechanism
U01$5,877,957 · 2
R44$4,099,987 · 3
R43$3,850,280 · 16
Top collaborators
No co-investigators on record.
Most similar at Inotek Pharmaceuticals Corporation
Same institution · by research overlap
- Andrew L Salzman$19,918,828
- Prakash Jagtap$6,029,479
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationRattusPlasmaMimeticsAcuteInjuryDosePharmaceutical PreparationsOxidation-ReductionPharmacodynamicsLungSafetyNitric OxideAntioxidantsAnimalsLipid PeroxidationPharmacologyIn VivoInfiltrationResuscitationCanis FamiliarisMitochondriaHistologicInnovation
Grant awards (30)
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$821,853
U01 · FY2018 · ES · contact PI
Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock$719,358
R44 · FY2018 · GM · contact PI
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$781,772
U01 · FY2017 · ES · contact PI
Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock$749,330
R44 · FY2017 · GM · contact PI
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$810,596
U01 · FY2015 · ES · contact PI
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur$774,459
U01 · FY2014 · ES · contact PI
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$644,944
U01 · FY2014 · ES · contact PI
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$648,083
U01 · FY2013 · ES · contact PI
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$681,561
U01 · FY2012 · ES · contact PI
A Thioredoxin Mimetic for Radiocontrast Nephropathy$260,513
R43 · FY2012 · DK · contact PI
Peroxynitrite Decomposition Catalyst and Nitric Oxide Donor for Endotoxemia$252,296
R43 · FY2012 · GM · contact PI
A Hybrid PARP Inhibitor and Redox Catalyst for Lung Transplantation$249,465
R43 · FY2012 · HL · contact PI
Bifunctional Nitric Oxide Donor Refractory to Nitrate Tolerance$240,508
R43 · FY2012 · HL · contact PI
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$36,753
U01 · FY2012 · ES · contact PI
Multifunctional therapeutics for treatment of acute chlorine inhalational injury$677,936
U01 · FY2011 · ES · contact PI
Bifunctional Modulation of Redox Imbalance for Treatment of Septic Shock$243,702
R43 · FY2011 · GM · contact PI
Bifunctional Redox Agent for the Treatment of PPHN$237,906
R43 · FY2011 · HL · contact PI
Novel therapy for female sexual dysfunction$1,463,183
R44 · FY2004 · HD
Novel anti-oxidant catalyst to treat IL-2 toxicity$340,727
R43 · FY2003 · CA
Nitric oxide donor therapy for diabetic foot$269,652
R43 · FY2003 · DK
A NITRIC OXIDE SYNTHASE INHIBITOR FOR INTESTINAL POLYPOS$250,000
R43 · FY2002 · CA
Endothelial dysfunction in atherosclerosis$209,902
R43 · FY2002 · HL
Cancer radiotherapy: sensitization by inhibitors of PAR*$205,022
R43 · FY2002 · CA
Antidiabetic effects of inosine$135,417
R43 · FY2002 · DK
NITRIC OXIDE SYNTHASE INHIBITOR FOR INTESTINAL POLYPOSIS$250,000
R43 · FY2001 · CA
A novel nonthrombogenic vascular circuit$151,328
R43 · FY2001 · HL
Novel therapy for female sexual dysfunction$100,000
R43 · FY2001 · HD
ANTI-OXIDANT THERAPY OF SMOKE INHALATION INJURY$1,168,116
R44 · FY2000 · HL
ANTIOXIDANT EXPERIMENTAL THERAPY OF CIRCULATORY SHOCK$240,777
R43 · FY2000 · HL
A NITRIC OXIDE SYNTHASE INHIBITOR FOR UVEITIS$213,065
R43 · FY2000 · EY